BioWaveGO, BioWaveHOME and BioWavePRO neurostimulators all utilize the same unique signal-mixing technology to deliver electrical signals through skin into deep tissue to the surface of nerves for inhibiting pain transmission and improving function. The signal technology is covered by numerous U.S. and international patents.
More than 84% of Patients Respond to BioWave
Multiple clinical studies show that more than 84% of patients experience a significant reduction in pain.* It literally gets them “back in the game”. BioWave neurostimulators can be used to reduce chronic, acute or post-operative pain and improve function including an increase in range of motion, decrease in stiffness and reduction of muscle spasm for an extended period of time following a 30 minute treatment.
Pick a Body Part – Any Body Part
BioWave neurostimulators can be used to treat numerous locations on the body including directly over or surrounding the sacral, lumbar, thoracic and cervical spine, hip, groin, knee, shoulder, ankle, foot, elbow, wrist, hand, and finger. Doctors, physical therapists, and athletic trainers report excellent results treating pain from acute and chronic tendinopathies, joint sprains, trigger points, osteoarthritis, pelvic floor pain including interstitial cystitis and post-operative pain.
BioWave Scores Big with Athletes
Professional athletes that use BioWavePRO, BioWaveHOME, or BioWaveGO have reported they experience better pain relief and functional improvement than with any other form of electrical stimulation and request to be treated with BioWave every time they return to the training room, while in meetings, or at home.
Clinical Studies and Reviews
BioWave is as well-researched and well-documented as it is well-received. Read the studies that have helped make BioWave the patented, proven, smarter pain blocking technology.
An Open-Label Pilot Study Investigating Noninvasive High-Frequency Peripheral Nerve Fiber Stimulation in Chronic Pain
D.A. Hegarty, B. Bretherton. Pain Management and Neuromodulation, Mater Private Hospital, Cork; Department of Anesthesiology, School of Medicine, University College, Cork, Ireland; School of Biomedical Sciences, Faculty of Biological Sciences, University of Leeds, Leeds; Pain Management Department, Leeds Teaching Hospitals NHS Trust, Leeds, UK
Post-operative pain treatment following total knee replacement surgery using BioWavePENS
T. Wanich, J. Gelber, R. Windsor, S. Rodeo. A randomized controlled pilot study to determine average maximum intensity settings, safety, and initial efficacy in terms of pain reduction, increased range of motion, and reduced pain medications, for a percutaneous neuromodulation pain therapy device (“BioWavePENS®”) following post-operative treatments for total knee replacement procedures.
Eastern Orthopaedic Association 39th Annual Meeting, October 22-25, 2008, Ritz-Carlton, Lake Las Vegas, Henderson, Nevada
American Academy of Orthopaedic Surgeons 2009 Annual Meeting, February 25-28, 2009, Las Vegas, Nevada
Treatment of chronic pain from osteoarthritis of the knee using BioWavePENS
Brian J. Cole, MD, MBA; Richard Kang, MD, MS; Paul B. Lewis, MD, MS; Adam Kramer, ATC; Jennifer K. Hayden, RN, MSN; Randomized Single-blinded Controlled Clinical Trial of a BiowavePENS device (Percutaneous Electrical Nerve Stimulation) versus Sham PENS treatment for the Osteoarthritic Knee. Orthopedics, June 2007, Volume 30, Number 6.
Treatment of pain from acute sports injuries using BioWavePRO
S. Panchal, J. Pergolizzi. White Paper on use of a neuromodulation pain therapy device (“BioWavePRO”) to treat acute sports injuries on New York Giants football players. 600 treatments on 80 players from June 2003 – December 2005. Unpublished manuscript, 2006.
Evaluation of optimal signal frequency and efficacy of BioWave
S. Diwan, H.C. Hemmings, R.F. Eliazo, S. Panchal. Symptomatic treatment of chronic low back pain: determination of optimal signal frequency and preliminary efficacy of a targeted noninvasive electronic pain control device. Anesth. Analg. Abstracts 96 S-1-S: 293, 2003.
Randomized, Double-Blinded, Comparative Crossover Trial Comparing Biowave vs TENS
S. Diwan MD, H. Hemmings MD, PhD, S. Panchal MD, Summary of a Randomized, Double-Blinded, Comparative Crossover Trial of the Safety and Efficacy of a Non-Invasive Targeted Electronic Pain Control Device (“Biowave System”) Versus Transcutaneous Electrical Nerve Stimulation (TENS) for the Symptomatic Treatment of Chronic Low Back Pain; March 2006.
Long Term Use of BioWaveHOME for the Treatment of Chronic Pain in Veterans
L. Kleinwaks, M. Rogers, D. McGurl.Long Term Use of BiowaveHOME High Frequency Neurostimulation for the Treatment of Chronic Pain in Veterans Following Successful BiowavePRO Neurostimulation Therapy in Veterans Administration Hospitals. White Paper, October 2017.
DISCLAIMER: This White Paper contains additional clinical information regarding BioWave and is provided for informational purposes only. Musculoskeletal Clinical Regulatory Advisors, LLC (MCRA), an independent organization, prepared this White Paper; the methodology used by MCRA in preparing the White Paper is set forth in the document, including on pages 2-4. Preparation of the White Paper was funded by BioWave Corporation. The White Paper neither constitutes nor implies an endorsement by the United States Government, the U.S. Department of Veteran Affairs, the Veteran’s Health Administration or any other governmental entity or organization. Consult your physician or health provider about whether treatment with a BioWave device is right for you.
Thank you and congratulations!!! I see a VERY BRIGHT FUTURE for BioWave!"
A lot more time to Spend doing things pain free !!! Thanks Biowave and Ron Steelman for going to bat for all Veterans with a pain deterrent that works and no opioids, or at least cutting use of opioids by 50 % .in my case 100 % opioids free. I hereby authorize Biowave to use my testimony."